Table 4 Stop statements in three systematic reviews with an IfR statement

Ghersi et al., 2015, https://doi.org/10.1002/14651858.CD003366.pub3

“Breast cancer management has evolved considerably since the first version of this review. Specifically, there is an increasing emphasis on the different biological subtypes of breast cancer and a rapidly developing array of targeted therapies to be used in place of or as adjuncts to cytotoxic chemotherapy. Thus the results of this review, which was confined to trials of chemotherapy alone, are unlikely to change, and further updates are not planned.”

Kunath et al., 2014, https://doi.org/10.1002/14651858.CD009266.pub2

“The quality of evidence according to GRADE is only moderate. However, we believe that further research on non-steroidal antiandrogen monotherapy is likely not necessary for the subgroup of men with metastatic prostate cancer.”

Non-Small Cell Lung Cancer Collaborative Group, 2010, https://doi.org/10.1002/14651858.CD007309.pub2

“The current meta-analysis suggests that we do not need another trial of supportive care alone versus supportive care and chemotherapy.”